Literature DB >> 2114034

Basis and implications of selectively diminished cytokine production in neonatal susceptibility to infection.

C B Wilson1, D B Lewis.   

Abstract

The human neonate is unduly susceptible to infection with viruses and other pathogens, such as Toxoplasma and Listeria, that survive and replicate within cells. Cellular immunity is the major mechanism of host defense against these intracellular pathogens. Selective immaturity in certain functions of T lymphocytes appears to be a major factor in the neonate's susceptibility to these infections. Particularly striking is the deficiency in production of interferon-gamma. We review the data regarding the deficiency in the production of interferon-gamma by cells of healthy and infected neonates, discuss what is known regarding the cellular and molecular mechanisms for this deficiency, and review the unique role played by interferon-gamma in host defense against intracellular pathogens. The response of the neonate's effector cells to the immunoenhancing effects of interferon-gamma appears to be variable; diminished enhancement by interferon-gamma of cytotoxic cell function and the production of tumor necrosis factor by macrophages may further compound the effects of diminished production of interferon-gamma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114034     DOI: 10.1093/clinids/12.supplement_4.s410

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  27 in total

1.  Neonatal dendritic cells are intrinsically biased against Th-1 immune responses.

Authors:  C L Langrish; J C Buddle; A J Thrasher; D Goldblatt
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

2.  Selective deficiency in protein kinase C isoenzyme expression and inadequacy in mitogen-activated protein kinase activation in cord blood T cells.

Authors:  Charles S T Hii; Maurizio Costabile; George C Mayne; Channing J Der; Andrew W Murray; Antonio Ferrante
Journal:  Biochem J       Date:  2003-03-01       Impact factor: 3.857

Review 3.  Neonatal innate immunity to infectious agents.

Authors:  László Maródi
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

4.  Influence of ERK activation on decreased chemotaxis of mature human cord blood monocyte-derived dendritic cells to CCL19 and CXCL12.

Authors:  Geling Li; Sunanda Basu; Myung-Kwan Han; Young-June Kim; Hal E Broxmeyer
Journal:  Blood       Date:  2006-12-19       Impact factor: 22.113

Review 5.  Current understanding of Pneumocystis immunology.

Authors:  Michelle N Kelly; Judd E Shellito
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

6.  Susceptibility to Pneumocystis carinii infection: host responses of neonatal mice from immune or naive mothers and of immune or naive adults.

Authors:  B A Garvy; A G Harmsen
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

7.  Chemiluminescent and flow cytometric analysis of gamma interferon preincubation on neonatal and adult rat polymorphonuclear leukocytes.

Authors:  R R Wittler; M M Lieberman; D D Paine; S L Muehlbauer; J E Lima; D M Sachanandani; C A Pinney
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

8.  Th1/Th2 patterns and balance in cytokine production in the parents and infants of a large birth cohort.

Authors:  Marilyn Halonen; I Carla Lohman; Debra A Stern; Amber Spangenberg; Dayna Anderson; Sara Mobley; Kathy Ciano; Michael Peck; Anne L Wright
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 9.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

10.  Acquisition of adult-like TLR4 and TLR9 responses during the first year of life.

Authors:  Muriel Nguyen; Elke Leuridan; Tong Zhang; Dominique De Wit; Fabienne Willems; Pierre Van Damme; Michel Goldman; Stanislas Goriely
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.